Cushing's Syndrome Treatment Market, By Treatment(surgery, Radiation Therapy, Medication), By Drug type (Ketoconazole, Etomidate, Pasireotide, and Aminoglutethimide), By End-user (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Clinics, e-Commerce/Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Cushing’s syndrome is characterized by the presence of excess steroid hormone cortisol or stress hormone in blood vessel. Mostly it is due to steroid drugs, but it can also occur from overproduction of cortisol by the adrenal glands. Treatment options include reducing steroid use, surgery and others. This type of syndrome includes symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing’s syndrome is caused by pituitary adenoma, and multiple endocrine neoplasia. Mostly side effects seen in this syndrome are diarrhea, nausea, high blood sugar or diabetes, headache, abdominal pain, and fatigue. Drugs use to control the production of cortisol include ketoconazole, mitotane (Lysodren) and metyrapon (Metopirone). Mifepristone (Korlym, Mifeprex) are approved for people who have type 2 diabetes or glucose intolerance.

Cushing’s syndrome is also seen in dogs which are mainly marked by lethargy and poor hair coat with bloated or pot-bellied appearance. The increased appetite is a direct result of elevated levels of cortisol. Life expectancy of a dog diagnosed varies, based on various factors like age, other health issues, genetics and plain old resiliency and ranges from 2-6 years. 

Impact of Covid-19 pandemic on market

People suffering from Cushing’s syndrome are more susceptible to COVID-19 as their immune system is weak in comparison to healthy people. So due to this, patients having this syndrome were increasingly hospitalized during this pandemic period.

Cushing’s syndrome is characterized by the presence of excess steroid hormone cortisol or stress hormone in blood vessel. Mostly it is due to steroid drugs, but it can also occur from overproduction of cortisol by the adrenal glands. Treatment options include reducing steroid use, surgery and others. This type of syndrome includes symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing’s syndrome is caused by pituitary adenoma, and multiple endocrine neoplasia. Mostly side effects seen in this syndrome are diarrhea, nausea, high blood sugar or diabetes, headache, abdominal pain, and fatigue. Drugs use to control the production of cortisol include ketoconazole, mitotane (Lysodren) and metyrapon (Metopirone). Mifepristone (Korlym, Mifeprex) are approved for people who have type 2 diabetes or glucose intolerance.

Cushing’s syndrome is also seen in dogs which are mainly marked by lethargy and poor hair coat with bloated or pot-bellied appearance. The increased appetite is a direct result of elevated levels of cortisol. Life expectancy of a dog diagnosed varies, based on various factors like age, other health issues, genetics and plain old resiliency and ranges from 2-6 years. 

Biotechnology boosting the Global Cushing’s Syndrome Treatment Market

Invention of new technologies is a large market opportunity for Cushing’s syndrome treatment market. The development of new drugs with minimal side effects drives the market of this particular syndrome. For instance, the U.S. Food and Drug Administration approved Isturisa (osilodrostat) oral tablets for adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease .Support for orphan diseases and imaging by government is the driving factor for this market. The ageing world’s population and increasing healthcare expenditure around the world are the driving factors. The relapse rate of Cushing’s syndrome after surgery is as high as 15%-20% which is also one of the driving factor.

High cost of drugs and its side effects

Lack of awareness regarding the latest treatments in the underdeveloped economics can restrain the market. One of the major restrain is high cost of drugs with their side effects which can’t be afforded by the population. However, technical and clinical-related challenges might also hamper growth of the global market to a certain extent.

On the basis of End-user, the target market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores, Clinics, e-Commerce/Online Pharmacies.  Based on treatment, the target is segmented into surgery, radiation therapy, medications. On the basis of drugs, the Cushing’s syndrome treatment market is segmented in Ketoconazole, Etomidate, Pasireotide, and Aminoglutethimide.

Regional Insights:

In North America, the U.S. is the dominant market for Cushing’s syndrome treatment because of latest technology and large purchasing power. The excellent reimbursement and growing incidence of Cushing’s syndrome are also expected to support the growth of the market. Besides, presence of key players such as Novartis AG, Pfizer Inc. and others is also expected to drive the growth of the Cushing’s syndrome treatment market in the U.S. The healthcare expenditure in the U.S. was estimated as 16% of its GDP in 2017, which imply better pricing and market attractiveness.

The second dominant market for Cushing’s syndrome treatment is Europe which is dominated by Germany owing to the presence of large medical industry and presence of advanced players, such as HRA Pharma. The growing healthcare infrastructure due to healthcare expenditure of Europe, which accounts to average 10 % of the GDP, are factors driving the growth of the Europe Cushing’s Syndrome treatment market. Other European nations with a sizeable market are France, the U.K. and Spain.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Global Cushing’s Syndrome Treatment Market report based on application, End-user and region.

Global Cushing’s syndrome Treatment Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Cushing’s syndrome treatment market are Pfizer, Corcept Therapeutics Inc., Novartis, Strong Bridge Biopharma, Orphagen Pharmaceuticals, Inc., and HRA Pharma.

Key Highlights:

•    In November 2019, Osilodrostat, which is used for the treatment of patients with Cushing syndrome in adults, received positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Furthermore, on 6th March 2020, Isturisa (osilodrostat), has been approved by the U.S Food and Drug Administration (FDA). Isturisa (osilodrostat) is an oral tablet used in the patients who cannot go for pituitary gland surgery or has not been curative.

•    In September 2019, positive results from phase 3 clinical trial of RECORLEV (levoketoconazole) drug was announced by Strong bridge Biopharma plc.. RECORLEV (levoketoconazole) drug is used for the treatment of endogenous Cushing’s syndrome.

• In June 2018, Pasireotide drug (Signifor, Novartis), which is used for the treatment of patients with Cushing syndrome who cannot go for pituitary gland surgery or has not been curative., had been approved by the U.S Food and Drug Administration (FDA).

• Pfizer
• Novartis
• Strong Bridge Biopharma
• Orphagen Pharmaceuticals, Inc.
• HRA Pharma
• Corcept Therapeutics, Inc.